The Esteem® Hearing Implant Post Approval Study
Status: | Completed |
---|---|
Conditions: | Other Indications, Other Indications |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | 18 - 90 |
Updated: | 4/21/2016 |
Start Date: | March 2011 |
End Date: | January 2016 |
To Evaluate the Long-term Safety and Efficacy of the Esteem® Hearing Implant in Subjects Suffering From Moderate to Severe Hearing Loss
The purpose of this study is to evaluate the long-term safety and efficacy of the Esteem®
Hearing Implant in subjects suffering from moderate to severe hearing loss.
Hearing Implant in subjects suffering from moderate to severe hearing loss.
The Post Approval Study is an extension of the pivotal clinical trial, which was designed as
a prospective, multi-center, non-randomized, clinical trial to evaluate the safety and
efficacy of the Esteem® System. For this trial the subject acts as his or her own control.
This trial has been designed to meet the United States' regulatory requirements.
The subjects included in this study include the 57 subjects implanted under the original IDE
study and the five (5) subjects implanted under the continued access expansion approved by
the FDA. Of these 62 subjects, all but one (explant) are available for continued follow-up.
These subjects will be re-consented for the 5 year Post Approval Study. No new subjects will
be enrolled and implanted in this study. The goal will be to monitor the 61 remaining
subjects through their five (5) year follow-up.
The following questions are to be answered:
- Is the Esteem effective through 5 year follow-up?
- Is the Esteem safe through 5 year follow-up?
a prospective, multi-center, non-randomized, clinical trial to evaluate the safety and
efficacy of the Esteem® System. For this trial the subject acts as his or her own control.
This trial has been designed to meet the United States' regulatory requirements.
The subjects included in this study include the 57 subjects implanted under the original IDE
study and the five (5) subjects implanted under the continued access expansion approved by
the FDA. Of these 62 subjects, all but one (explant) are available for continued follow-up.
These subjects will be re-consented for the 5 year Post Approval Study. No new subjects will
be enrolled and implanted in this study. The goal will be to monitor the 61 remaining
subjects through their five (5) year follow-up.
The following questions are to be answered:
- Is the Esteem effective through 5 year follow-up?
- Is the Esteem safe through 5 year follow-up?
Inclusion Criteria:
Subject must meet all of the following criteria to be eligible for treatment in the trial:
1. Subject is at least 18 years old
2. Subject understands the nature of the procedure and has signed the Subject Informed
Consent Form prior to the procedure
3. Subject is willing and able to comply with specified follow-up evaluations and
understands the audiological test procedures and use of the Esteem® System.
4. Subject has moderate to severe sensorineural hearing loss between 500 and 4000 Hz in
the ear to be implanted with pure tone air-conduction threshold levels within the
limits of a Hearing Aid (HA) as follow:
Freq (Hz) 500 1000 2000 3000 4000 Lower Level (dB HL) 30 35 35 35 35 Upper Level (dB
HL) 100 100 100 100 100
5. Subject's air-bone gap is no greater than 10 dB at 4 of the 5 following frequencies:
500, 1000, 2000, 3000 and 4000 Hz.
6. Subject has an unaided maximum word recognition score of greater than or equal to 40%
with recorded delivery using a phonetically balanced word list at SRT + 40 dB or at
maximum tolerable presentation level.
7. Subject is a current user of a properly functioning and appropriately fit hearing
aid. This is defined as the subject has used this aid for at least four (4) hours
(average) per day (in the ear to be implanted) for at least three (3) months for a
new aid or one (1) month for an adjusted aid.
8. Subject's hearing aid, in the ear to be implanted, shall appropriately fit optimally.
9. Subject has normally functioning eustachian tube
10. Subject has normal tympanic membrane
11. Subject has a normal middle ear anatomy
12. Subject has adequate space for Esteem® System implant determined via fine cut
temporal bone CT scan
13. Subject is a native speaker of the English language.
14. Subject is a hearing aid user in the ear to be implanted
Exclusion Criteria:
Subjects will be excluded from the trial if any one of the following criteria is met:
1. Subject has a history of post-adolescent chronic middle ear infections, inner ear
disorders or recurring vertigo requiring treatment, disorders such as mastoiditis,
Hydrops or Meniere's syndrome or disease
2. Subject has a history of external otitis or eczema for the outer ear canal and the
investigator believes this will affect the Esteem® System implantation
3. Subject has cholesteatoma or destructive middle ear disease
4. Subject has life expectancy of less than two (2) years due to other medical
conditions
5. Subject has retrocochlear or central auditory disorders
6. Subject is known to be suffering from any psychological, developmental, physical, or
emotional disorder that the investigator feels would interfere with the surgery or
follow-up testing
7. Subject has a known history of fluctuating air conduction and/or bone conduction
hearing loss over a one-year period of 15 dB in either direction at 2 or more
frequencies (from 500 - 4000 Hz)
8. Subject has sudden hearing loss due to unknown cause
9. Subject has a history of disabling tinnitus, defined as tinnitus which required
treatment.
10. Subject is unable to adequately perform audiological testing
11. Subject has a medical condition or undergoing a treatment that may affect healing and
the investigator does not believe the subject is a good candidate for the trial.
12. Subject has diabetes that is not well controlled with medication or diet and the
investigator does not believe in his best medical judgment that the subject would be
a good candidate for the trial
13. Subject is pregnant at the time of device implant
14. Subject has a history of keloid formation
15. Subject has known hypersensitivity to silicone rubber, polyurethane, stainless steel,
titanium and/or gold
We found this trial at
5
sites
Click here to add this to my saved trials
Lahey Clinic When Frank Lahey, MD, founded a group practice in 1923, his vision was...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials